Ferrari, F., Bellone, S., Black, J., Schwab, C. L., Lopez, S., Cocco, E., . . . Santin, A. D. (2015). Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J Exp Clin Cancer Res.
शिकागो स्टाइल उद्धरणFerrari, Francesca, et al. "Solitomab, an EpCAM/CD3 Bispecific Antibody Construct (BiTE®), Is Highly Active against Primary Uterine and Ovarian Carcinosarcoma Cell Lines in Vitro." J Exp Clin Cancer Res 2015.
एमएलए उद्धरणFerrari, Francesca, et al. "Solitomab, an EpCAM/CD3 Bispecific Antibody Construct (BiTE®), Is Highly Active against Primary Uterine and Ovarian Carcinosarcoma Cell Lines in Vitro." J Exp Clin Cancer Res 2015.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.